PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

Failure of integrin inhibitors in clinical trials can be avoided by redesigning the chemical conformation of these proteins, as shown by a study led by Timothy Springer, a professor in the Department ...

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

Integrin α-4/β-7 - also known as Lymphocyte Peyer’s patch adhesion molecule-1 (LPAM-1) - is an integrin heterodimer composed of covalently linked α-4 and β-7 subunits. Expressed on the surface of ...

Pliant Therapeutics has shown positive interim results in clinical trials for PLN-74809, including a Phase 2a trial for the treatment of IPF. Pliant has several advantages over its competitors, ...

C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 ...

Panelists discuss several promising new agents for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including an LPA1 receptor antagonist showing lung function ...

A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one ...

Eli Lilly has agreed to acquire Morphic Therapeutic for approximately $3.2 billion, the companies said today, in a deal designed to bolster the buyer’s pipeline with chronic disease candidates led by ...